相关实验视频
Updated: Jul 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
由AURKA抑制剂诱导的PD-L1上调会损害抗瘤免疫反应
Bi Meng1,2,3, Xuan Zhao1,2,3, Shuchang Jiang4
1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
AURKA抑制剂MLN8237增加PD-L1的表达,可能增强瘤免疫疗法. 在临床前模型中,将MLN8237与抗PD-L1抗体结合,显著降低了瘤体积,并促进了T细胞透.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对PD-L1的瘤免疫疗法是一种强大的治疗策略.
- 瘤向药物通过调节PD-L1表达来影响瘤免疫微环境.
- 优化药物治疗方案对于增强瘤向治疗和免疫治疗疗效至关重要.
研究的目的:
- 研究临床前向药物对癌细胞PD-L1表达的作用.
- 探索AURKA在调节PD-L1表达中的作用.
- 评估AURKA抑制剂与抗PD-L1免疫疗法结合的治疗潜力.
主要方法:
- 流细胞计被用来评估PD-L1表达在向药物治疗后的各种癌症细胞系.
- 通过siRNA或CRISPR-Cas9.9来击倒AURKA.
- 瘤异种移植模型 (乳腺癌和结直肠癌) 用于评估治疗后的T细胞透和瘤生长.
主要成果:
- AURKA抑制剂MLN8237剂量依赖地增加了PD-L1的表达,并表现出抗瘤作用.
- 对AURKA的抑制导致PD-L1升调.
- 在乳腺瘤模型中,MLN8237治疗降低了CD3+和CD8+T细胞透率,但与抗PD-L1抗体的联合治疗显著降低了瘤体积,并在结直肠癌模型中增加了T细胞透率.
结论:
- MLN8237增强PD-L1表达,可能通过STAT3酸化.
- 将MLN8237与抗PD-L1抗体治疗结合起来,有望克服耐药性并改善瘤治疗结果.
- 这项研究为改善瘤向治疗和免疫治疗中的药物疗法提供了新的见解.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
相关概念视频
Inhibition of Cdk Activity
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
The JAK-STAT Signaling Pathway